Second-look laparotomy in ovarian carcinoma patients after 8 and after 12 courses of cisplatin-based chemotherapy.
Sixteen ovarian carcinoma patients who received 12 courses and 21 patients who received 8 courses of cisplatin-based combination chemotherapy were compared. The two groups showed similar rates of second-look laparotomy (10/16 vs. 14/21) and similar rates of negative second-look laparotomies (6/10 vs. 9/14). The advantages of earlier reexploration are possibly lower toxicity and earlier recognition of patients with tumors resistant to the initial chemotherapy.
Menczer
J
J
Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Ben-Baruch
G
G
Modan
M
M
Brenner
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007813:Laparotomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012086:Reoperation
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin